

1 Humoral immune response of patients infected by earlier lineages of SARS-CoV-2 neutralizes
2 wild types of the most prevalent variants in Brazil
3

4 Alex Pauvolid-Corrêa^{1,2}, Braulia Costa Caetano¹, Ana Beatriz Machado¹, Mia Araújo Ferreira¹,
5 Natalia Valente¹, Thayssa Keren Neves¹, Kim Geraldo³, Fernando Motta¹, Valdiléa Gonçalves
6 Veloso dos Santos³, Beatriz Grinsztejn³, Marilda Mendonça Siqueira¹, Paola Cristina Resende¹
7

8 ¹Laboratório de Vírus Respiratórios e Sarampo, COVID-19 National Reference Laboratory of
9 Brazil and World Health Organization COVID-19 Reference Laboratory, Instituto Oswaldo
10 Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.

11 ²Department of Veterinary Integrative Biosciences, Texas A&M University, College Station,
12 Texas, United States of America.

13 ³Instituto Nacional de Infectologia Evandro Chagas (INI), Fiocruz, Rio de Janeiro, Brazil.
14

15 Abstract

16
17 In the present study, serum samples of 20 hospitalized COVID-19 patients from Brazil who were
18 infected by the earlier SARS-CoV-2 lineages B.1.1.28 and B.1.1.33, and by the variant of
19 concern (VOC) Gamma (P.1) were tested by plaque reduction neutralization test (PRNT₉₀) with
20 wild isolates of a panel of SARS-CoV-2 lineages, including B.1, Zeta, N.10, and the VOCs
21 Gamma, Alpha, and Delta that emerged in different timeframes of the pandemic. The main
22 objectives of the present study were to evaluate if serum of COVID-19 patients infected by
23 earlier lineages of SARS-CoV-2 were capable to neutralize recently emerged VOCs, and if
24 PRNT₉₀ is a reliable serologic method to distinguish infections caused by different SARS-CoV-2
25 lineages. Overall, sera collected from the day of admittance to the hospital to 21 days after
26 diagnostic of patients infected by the two earlier lineages B.1.1.28 and B.1.1.33 presented
27 neutralizing capacity for all challenged VOCs, including Gamma and Delta, that were the most
28 prevalent VOCs in Brazil. Among all variants tested, Delta and N.10 presented the lowest mean
29 of neutralizing antibody titers, and B.1.1.7, presented the highest titers. Four patients infected
30 with Gamma, that emerged in December 2020, presented neutralizing antibodies for B.1,
31 B.1.1.33 and B.1.1.28, its ancestor lineage. All of them had neutralizing antibodies under the
32 level of detection for the VOC Delta. Interestingly, patients infected by B.1.1.28 presented very
33 similar mean of neutralizing antibody titers for both B.1.1.33 and B.1.1.28. Findings presented
34 here indicate that most patients infected in early stages of COVID-19 pandemic presented
35 neutralizing antibodies up to 21 days after diagnostic capable to neutralize wild types of all
36 recently emerged VOCs in Brazil, and that the PRNT₉₀ it is not a reliable serologic method to
37 distinguish natural infections caused by different SARS-CoV-2 lineages.
38

39 Introduction

40
41 The ongoing pandemic of coronavirus disease 2019 (COVID-19) is a major healthcare
42 threat worldwide. While viral RNA-based testing for acute infection of severe acute respiratory
43 syndrome coronavirus 2 (SARS-CoV-2) is the current standard, surveying antibodies is
44 necessary not only to determine the past exposure, but also to identify donors with high-
45 neutralizing titers for convalescent plasma for therapy [1]. Despite the relationship between
46 humoral response and clinical protection from SARS-CoV-2 infection remains not fully

47 understood, some studies have confirmed neutralizing antibodies as an immune correlate of
48 protection [2]. The humoral immune response can block infection through neutralizing
49 antibodies, which bind the virus in a manner that prevents host cell infection [3]. The host
50 humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, has been
51 examined mostly by ELISA-based assays using recombinant viral nucleocapsid protein or
52 pseudovirus-based neutralization assays [4]. Coronavirus infections typically induce neutralizing
53 antibody responses, and virus neutralization assays performed on cell cultures, as plaque
54 reduction neutralization test (PRNT), are considered as gold standard for serological testing and
55 determining immune protection [1]. Although antiviral T and B cell memory certainly contribute
56 some degree of protection, strong evidence of a protective role for neutralizing serum antibodies
57 exists [5]. Neutralizing antibody levels are highly predictive of immune protection from
58 symptomatic SARS-CoV-2 infection [2].

59 Since the pandemic began in China in December 2019, thousands of SARS-CoV-2
60 lineages have emerged worldwide [6]. The variants that presented increased transmissibility,
61 virulence, and decreased response to available diagnostics, vaccines, and therapeutics were
62 defined by the World Health Organization as variant of concern (VOC) [7]. Following the
63 upsurge of variants, several reinfection cases started to be reported worldwide rising questions
64 about the efficiency of humoral response mounted after primary infections to prevent a
65 secondary infection by SARS-CoV-2 [8]. In fact, some recent studies have experimentally
66 demonstrated that monoclonal antibodies, convalescent plasma of individuals infected by earlier
67 lineages, and serum collected from vaccinees have a reduced neutralizing capacity when
68 challenged with the recently emerged VOCs of SARS-CoV-2 [9–11].

69 The cross-reactivity of humoral responses among all different lineages of SARS-CoV-2
70 including VOCs, as well as the potential use of specific serological methods as PRNT to
71 distinguish lineage infections remain unclear. Several lineages of SARS-CoV-2 have been
72 reported in Brazil by the consortium COVID-19 Fiocruz Genomics Surveillance Network of the
73 Brazilian Ministry of Health (<http://www.genomahcov.fiocruz.br/dashboard/>). Among the most
74 important lineages detected in the country were the VOCs Gamma, Delta and Alpha, as well as
75 the Zeta, B.1, B.1.1.28, B.1.1.33 and N.10. The main objectives of the present study were to
76 assess the capacity of sera of COVID-19 patients infected by earlier lineages of SARS-CoV-2 to
77 neutralize the two most prevalent VOCs in Brazil, and to evaluate if PRNT₉₀ is a reliable
78 serologic method to distinguish infections caused by different SARS-CoV-2 lineages.

79

80 **Methods**

81

82 *Case description:* Swab and serum samples were periodically collected from hospitalized
83 COVID-19 patients that were admitted to the COVID-19 Hospital of the National Institute of
84 Infectious Diseases, Rio de Janeiro. Samples were weekly collected from the day of admittance
85 to up 21 days after diagnostic. The index cases were patients aged 18 years and older, with
86 SARS-CoV-2 infection confirmed by real-time reverse transcription polymerase chain reaction
87 (qRT-PCR) in respiratory samples, which consisted of a combination of two nasopharyngeal
88 swabs and one oropharyngeal swab collected in 3 mL of viral transportation medium (VTM).

89

90 *qRT-PCR for SARS-CoV-2:* The VTM of respiratory samples were submitted to RNA extraction
91 using Chemagic Viral DNA/RNA 300 kit H96 in a Janus G3 automated workstation (Perkin
92 Elmer, www.chemagen.com). SARS-CoV-2 was detected by qRT-PCR assays targeting the viral

93 gene E. Reactions were performed using the Kit Molecular SARS-CoV-2 (E/RP) (Bio-
94 Manguinhos/IBMP, Brazil).

95
96 *Whole-genome sequencing:* Positive samples eligible for whole-genome sequencing had RNA
97 extracted using the QIAamp Viral RNA Mini Kit (QIAGEN) or using Chemagic Viral
98 DNA/RNA 300 kit H96 in a Janus G3 automated workstation (Perkin Elmer,
99 www.chemagen.com). The SARS-CoV-2 genomes were recovered by amplification of long
100 segments (2kb), according to a protocol developed by COVID-19 Fiocruz Genomic Surveillance
101 Network to recover high-quality genomes (P.C. Resende, unpub. data,
102 doi.org/10.1101/2020.04.30.069039). Segment libraries were then sequenced in Illumina MiSeq.
103 The FASTQ reads obtained were imported into the CLC Genomics Workbench version 20.0.4
104 (QIAGEN), trimmed, and mapped against the reference sequence hCoV-19/Wuhan/WIV04/2019
105 (GISAID access number EPI_ISL_402124) to obtain the final genome consensus. The SARS-
106 CoV-2 lineage characterization was performed by Pango Network [12]. All genomic and
107 epidemiological data associated were uploaded at the EpiCoV database in the GISAID
108 (www.gisaid.org).

109
110 *Isolation of SARS-CoV-2 reference lineages used for PRNT:* As part of the Brazil's Surveillance
111 Network for Respiratory Illnesses, respiratory samples collected in sentinel units located in
112 different states of the country are routinely sent to the Reference Laboratory. Eligible samples
113 that tested positive for different lineages of SARS-CoV-2 were submitted to virus isolation in
114 Vero E6 or Vero CCL-81 cells at a Biosafety level 3 Laboratory, as previously described [13].
115 Briefly, 200 μ L of each respiratory sample were inoculated in cell cultures, which were then
116 inspected daily for cytopathic effect (CPE), up to four days. For each sample, isolation was
117 attempted in a maximum of three consecutive blind passages. Overall, in positive cultures, CPE
118 started on second day post-infection and viral harvest was performed at the fourth day post-
119 infection. When CPE was observed, culture supernatants were aliquoted in working stocks and
120 an aliquot submitted to qRT-PCR followed by nucleotide sequencing for lineage confirmation.
121 Once confirmed, the consensus sequences were deposited at the EpiCoV data base on GISAID
122 (www.gisaid.org), and one representative of each SARS-CoV-2 lineage sequentially titrated by
123 lysis plaque assay, to form a lineage bank with reference isolates.

124
125 *PRNT:* Subsets of serum samples of hospitalized patients that were positive for different lineages
126 of SARS-CoV-2 were selected for PRNT. For the patients who had several blood samples
127 collected during hospitalization, the last samples were preferred. Briefly, sera were heat-
128 inactivated at 56°C for 30 minutes do inactivate the complement system. Inactivated serum
129 samples were submitted to PRNT₉₀ in Vero CCL-81 cells in duplicate at serial 2-fold dilutions to
130 determine 90% endpoint titers against five infectious SARS-CoV-2 reference lineages isolates.
131 The panel of reference isolates used for PRNT included the lineages B.1 (hCoV-19/Brazil/RJ-
132 FIOCRUZ-314/2020, GISAID accession number EPI_ISL_414045), B.1.1.28 (hCoV-
133 19/Brazil/AL-FIOCRUZ-33444-1P/2020, EPI_ISL_2645638), B.1.1.33 (hCoV-19/Brazil/RJ-
134 FIOCRUZ-20136-1P/2020, EPI_ISL_1181430), Zeta (hCoV-19/Brazil/PB-FIOCRUZ-33096-
135 1P/2020, EPI_ISL_1402429), N.10 (hCoV-19/Brazil/MA-FIOCRUZ-6871-1P/2021,
136 EPI_ISL_3828018), and the VOCs Gamma (hCoV-19/Brazil/AM-FIOCRUZ-3521-1P/2021,
137 EPI_ISL_1402431), Alpha (hCoV-19/Brazil/RJ-FIOCRUZ-2624-1P/2021, EPI_ISL_1402430)
138 and Delta (hCoV-19/Brazil/MA-FIOCRUZ-25688-2P/2021, EPI_ISL_2645417). Neutralizing

139 antibodies were quantified, and serum samples were considered seropositive when at least 1:10
140 dilution reduced $\geq 90\%$ of the formation of SARS-CoV-2 plaque forming units (PFU), as
141 previously reported [14].

142

143 **Ethics**

144

145 This study was approved by the Ethics Committee of the Fundação Oswaldo Cruz (CAAE
146 68118417.6.0000.5248), and the Ethics Committee of the National Institute of Infectious
147 Diseases (CAAE 32449420.4.1001.5262). All patients entering the study were required to read
148 and sign an informed consent form.


149

150 **Results**

151

152 From a population of patients recruited from May 2020 to August 2021, we were able to
153 obtain a panel of sera of individuals infected by SARS-CoV-2 lineages B.1.1.28, B.1.1.33, the
154 two most common lineages in early pandemic [15] and Gamma, the first VOC to become
155 prevalent in Brazil [16]. From a total of 20 serum samples evaluated, five were from patients
156 positive for B.1.1.28, four from patients that tested positive for Gamma, and 11 were positive for
157 B.1.1.33 (Table). Among five patients infected by B.1.1.28, highest neutralizing antibody titers
158 were observed for B.1.1.28, followed by Alpha, B.1.1.33, B.1, Gamma, Zeta, N.10 and Delta
159 (Figure). Among patients infected by B.1.1.33, similar profile was observed. Neutralizing
160 antibody titer mean was higher for B.1.1.33, followed by Alpha, B.1, B.1.1.28, Zeta, Gamma,
161 and with equally reduced neutralizing antibodies for Delta and N.10 (Figure). From four patients
162 infected by Gamma, highest PRNT₉₀ titers were observed for Gamma, followed by Alpha,
163 B.1.1.33, N.10, B.1.1.28 and Zeta, and with neutralizing antibodies under the level of detection
164 for Delta in all individuals (Table).

165



166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176

Figure: Anti-SARS-CoV-2 neutralizing antibodies titers in serum samples from COVID-19 patients admitted to a reference hospital in Rio de Janeiro, Brazil. Samples were obtained from patients infected with the SARS-CoV-2 lineages B.1.1.28 (top left), B.1.1.33 (top right) or Gamma (P.1, bottom panel). Samples were heat-inactivated, submitted to limiting dilution and then tested against different viral isolates (x axis of each panel) belonging to early pandemic lineages (B.1; B.1.1.28 and B.1.1.33), variants of interest (N.10 and P.2) and variants of concern (Alpha, Gamma, and Delta).

Table: PRNT₉₀ titers of convalescent sera of COVID-19 patients for different SARS-CoV-2 lineages

Patient ID	Lineage of infection	SARS-CoV-2 lineages							
		<i>B.1</i>	<i>B.1.1.28</i>	<i>B.1.1.33</i>	<i>N.10</i>	<i>Zeta</i>	<i>Alpha</i>	<i>Gamma</i>	<i>Delta</i>
COV029	B.1.1.28	80	160	160	40	80	80	80	40
COV161	B.1.1.28	40	160	160	10	10	80	20	10
COV168	B.1.1.28	80	320	320	20	20	≥320	40	10
COV167	B.1.1.28	160	320	160	20	20	≥320	10	40
COV178	B.1.1.28	40	80	80	40	40	80	40	<10
Geometric Mean	<i>B.1.1.28</i>	69.64	391.79	336	48.97	60.39	≥278.58	68.31	10.99
COV014	B.1.1.33	20	40	160	<10	20	40	10	<20
COV057	B.1.1.33	160	80	80	40	40	80	80	NT
COV008	B.1.1.33	160	80	160	80	80	160	80	20
COV051	B.1.1.33	40	40	160	20	40	160	80	<10
COV170	B.1.1.33	160	160	160	40	40	80	40	20
COV186	B.1.1.33	40	80	160	20	20	80	40	40
COV036	B.1.1.33	640	80	640	40	160	640	80	40
COV101	B.1.1.33	320	160	160	80	160	320	160	40
COV106	B.1.1.33	40	160	160	20	40	80	40	<10
COV150	B.1.1.33	80	320	160	10	20	80	20	10
COV146	B.1.1.33	320	160	320	160	160	320	80	≥320
Geometric Mean	<i>B.1.1.33</i>	109.63	225.93	391.49	72.85	121.47	317.44	115.47	≥12.34
COV381	Gamma	10	80	80	80	40	80	160	<10
COV373	Gamma	40	40	40	80	80	80	160	<10
COV385	Gamma	20	40	40	40	40	160	320	<20
COV386	Gamma	20	40	160	10	40	160	160	<10
Geometric Mean	Gamma	42.5	97.57	147.27	92.5	97.57	233.14	390.27	1

*NT: Not tested; for geometric mean calculation purposes, 1 was used for titers <10, and <20.

Discussion

The relationship between humoral response to SARS-CoV-2 antigens, especially the spike protein, and clinical protection from COVID-19 remains not fully understood, although some studies have confirmed neutralizing antibodies as an immune correlate of protection [2]. Likewise, it is still not completely understood to what extent the mutations in viral antigens contribute to virus evasion from neutralizing antibodies, and how significant this escape mechanism could be for the general effectiveness of the protective response, especially in the context of vaccinations, reinfections, and the evolution of the pandemic. It has been shown that mutations in the ACE2 binding site of variants result in an increased affinity for the receptor ACE2, and that changes outside the receptor-binding domain also impact neutralization [17]. In this scenario, we primarily investigated the neutralization profile of sera from patients infected by the most prevalent lineages in early pandemic in Brazil including B.1.1.33 and B.1.1.28, with the recently emerged VOCs including Gamma, Alpha, and Delta. Additionally, we investigated if Gamma-induced antibodies were capable to neutralize the early isolates and the most recently emerged VOC, Delta. We observed that, despite the variation in antibody levels, most serum samples of patients infected by early isolates presented some level of neutralizing activity against all VOCs. The reverse situation, in which serum samples from individuals infected with the Gamma lineage were challenged with early pandemic viral isolates, also produced detectable neutralization. However, when sera from Gamma-infected individuals were tested with other VOC Delta, the PRNT₉₀ titer was below the limit of detection of the assay (Table).

Gamma, which emerged from the B.1.1.28 lineage, contains 17 amino acid substitutions, ten of which in the spike protein, including N501Y, E484K and K417T in the receptor-binding domain, five in the N-terminal domain, and the mutation H655Y near the furin cleavage site [18]. These mutations reduce the neutralization capacity of convalescent sera from individuals infected by early isolates [11], and findings presented here suggest these mutations perhaps interfere also with the efficiency of its neutralizing antibodies for other variants, as Delta.

Despite the small number of patients evaluated, the findings that Gamma-induced immune sera presented low or absent PRNT₉₀ titers for Delta raises concern over the potential risk of reinfections, and consequent prolongation of the pandemic. Gamma was the most prevalent lineage of SARS-CoV-2 in Brazil for several months in a row, and now, people who were previously infected by Gamma are being exposed to Delta, which is currently the most prevalent VOC in the country [16]. In Brazil, Delta was first detected in May 2021, and by the end of August, 70% of the genomes of SARS-CoV-2 sequenced were Delta (www.genomahcov.fiocruz.br/dashboard/). As previously reported, this variant presents a higher replication fitness and decreased sensitivity to neutralizing antibodies mounted for early isolates, both contributing to higher transmissibility [19].

It is important to mention that the protective role of neutralizing antibodies does not seem to be directly linked to the titers in which they are found, but to timing and kinetics of their production, with studies suggesting a limited role of antibodies in predicting disease severity of the COVID-19, and that the earlier the presence of neutralizing antibodies after infection, the less severe is the disease outcome [20].

It is noteworthy that for most viruses there is no direct correlate of protection in humans, since the studies needed to establish such a correlate in humans are challenging. For instance, protective neutralizing antibody titers have been roughly estimated for yellow fever vaccine by challenge studies in nonhuman primates and hamster models [21, 22]. The threshold of protective neutralizing antibody titers for SARS-CoV-2 and its lineages has not been established. Therefore, lower neutralizing antibodies titers including the samples with titers under the limit of detection as <10 , do not necessarily mean susceptibility to a hypothetical secondary challenge. Samples that presented titers below 10 were not tested in lower dilutions, and if titers ≤ 9 are protective for each one of the different lineages of SARS-CoV-2 tested remain unknown.

Despite concerns over the potential risk of infections caused by Delta variant in patients previously exposed to Gamma, it is noteworthy that the number of reinfections reported worldwide remains limited, and that reinfections caused by Delta variant after previous infection by another VOC, as Gamma, have not been reported yet. The continuous advance of the COVID-19 vaccination has reduced the pace of new infections worldwide and is also expected to mitigate the number of reinfections as well. It is important to mention though that the time Delta variant became dominant in Brazil coincides with the local increasing vaccination coverage, but because of the unequal pace of vaccination throughout the country and along the time, Brazil remains with vaccination coverage below desirable. By the beginning of October 2021, over 58% of the adult population had been fully vaccinated in Brazil [23]. Regardless the recent improvement, a recent study conducted in the United States found that if in the state of Florida, the coverage was 74% instead of 59,5%, vaccination would have averted 664,007 additional cases, and reduced hospital admissions by 61,327, and deaths by 16,235 [24].

Finally, cellular immune response is believed to play also an important role in the immune response [5]. Cellular immune response was not investigated in the present study, and only with a combined evaluation of both immune responses for a better understanding of the relationship between neutralizing antibody titers and susceptibility to secondary infections.

Besides being considered markers of immune protection, specific neutralizing antibodies have also been used to evaluate viral exposure, and ultimately, for diagnostic purposes. Assays designed to detect neutralization antibodies have been widely used for the diagnostic of different viral groups. The PRNT is the most specific and gold standard serological test for the differentiation of closely related flavivirus infections, as dengue and yellow fever viruses in convalescent serum samples [25]. Type-specific antibodies can be distinguished using the PRNT, and two or more flaviviruses are distinct from each other by quantitative serological criteria. Four-fold or greater differences between PRNT titers have been used as seropositivity criterion in heterologous reactions [25,26]. In the present study, despite some genetic and immunogenic differences observed among all lineages of SARS-CoV-2 worldwide, these viruses are closely related and for that reason a PRNT with a highly conservative threshold of 90% neutralization in $\geq 1:10$ serum dilution was used as seropositivity criterion.

According to our findings, the four-fold or greater difference among PRNT titers was not a suitable seropositivity criterion to distinguish infections among the different lineages of SARS-CoV-2 tested. Convalescent serum from patients infected by B.1.1.28 presented a mean of PRNT titer very similar for B.1.1.28, B.1.1.33 and Alpha lineages, and the titer difference was less than four-fold greater than titers for B.1. Four-fold or greater titers for B.1.1.28 were observed only when compared to the titers of the variants N.10, Zeta and Delta.

The similar profile was observed for samples from patients infected by B.1.1.33. In this case, these patients presented a non-significant difference in PRNT titers between B.1.1.33, B.1

and Alpha. B.1.1.33-induced sera presented a mean of PRNT titer less than four-fold greater for B.1.1.33 when compared to B.1.1.28, Zeta and N.10. Four-fold or greater B.1.1.33 titers were observed only when compared to Gamma and Delta VOCs. Finally, for the patients previously infected by Gamma, PRNT titers for Gamma were more than four-fold higher for Gamma when compared to B.1 and B.1.1.28, Delta and Zeta. Differences were smaller than four-fold when compared to B.1.1.33, N.10, and Alpha. Of note, the mean of PRNT₉₀ titers for the Alpha variant was the second highest in all the three groups of patients, which includes samples of patients infected by B.1.1.28 and B.1.1.33 that were collected before the upsurge of Alpha variant in the United Kingdom.

The difference in PRNT₉₀ titers demonstrated here among all lineages indicate that the four-fold or greater criterion of seropositivity is not reliable to distinguish lineage infections. The same is truth if considering optionally two-fold or greater differences as criterion de seropositivity.

In conclusion, the humoral response mounted for more recently emerged variants after natural infections caused by earlier isolates and different lineages reported here, corroborates the importance of the international recommendation of a high vaccination coverage which has being instrumental to reduce severe cases and deaths, mitigate virus propagation, and the upsurge of new variants.

Acknowledgments

We gratefully acknowledge the patients and authors from the originating laboratories responsible for obtaining the specimens. We thank the funding support from General Laboratories Coordination of Brazilian Ministry of Health; the Coordination of Health Surveillance and Reference Laboratories of Oswaldo Cruz Foundation; Ministério da Ciência, Tecnologia, Inovações e Comunicações/Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq/Ministério da Saúde-MS/FNDCT/SCTIE/Decit (grants no. 402457/2020-9 and 403276/2020-9); Inova Fiocruz/Fundação Oswaldo Cruz (grants no. VPPCB-007-FIO-18-2-30; FAPERJ: E26/210.196/2020). We also thank the support of the Fiocruz COVID-19 Genomic Surveillance Network (<http://www.genomahcov.fiocruz.br>), the Respiratory Viruses Genomic Surveillance Network of the General Laboratory Coordination, Brazilian Ministry of Health, Brazilian Central Laboratory States, the Multi-user Research Facility of Biosafety Level 3 Platform of the Oswaldo Cruz Institute and Fiocruz Diagnoses Unit Rio de Janeiro.

References

1. **Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, et al.** Author Correction: A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat Commun* 2021;12:4000.
2. **Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, et al.** Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021;27:1205–1211.
3. **VanBlargan LA, Goo L, Pierson TC.** Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. *Microbiol Mol*

- Biol Rev* 2016;80:989–1010.
4. **Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, et al.** Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. *Clin Chem* 2019;66:1538–1547.
 5. **Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, et al.** SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* 2020;584:457–462.
 6. **Koyama T, Platt D, Parida L.** Variant analysis of SARS-CoV-2 genomes. *Bull World Health Organ* 2020;98:495–504.
 7. **Konings F, Perkins MD, Kuhn JH, Pallen MJ, Alm EJ, et al.** SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. *Nat Microbiol* 2021;6:821–823.
 8. **Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A.** The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. *J Clin Microbiol*;59. Epub ahead of print 19 March 2021. DOI: 10.1128/JCM.02769-20.
 9. **Vidal SJ, Collier AY, Yu J, McMahan K, Tostanoski LH, et al.** Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. *J Virol*;95. Epub ahead of print 2021. DOI: 10.1128/jvi.00404-21.
 10. **Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, et al.** Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*;184. Epub ahead of print 2021. DOI: 10.1016/j.cell.2021.06.020.
 11. **Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, et al.** Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*;184. Epub ahead of print 2021. DOI: 10.1016/j.cell.2021.03.055.
 12. **O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, et al.** Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. *Virus Evol* 2021;7:1–9.
 13. **Basile K, McPhie K, Carter I, Alderson S, Rahman H, et al.** Cell-based Culture Informs Infectivity and Safe De-Isolation Assessments in Patients with Coronavirus Disease 2019. *Clin Infect Dis* 2020;1–8.
 14. **Deshpande G, Sapkal G, Tilekar B, Yadav P, Gurav Y, et al.** Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. *Indian J Med Res* 2020;152:82.
 15. **Resende PC, Delatorre E, Gräf T, Mir D, Motta FC, et al.** Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil. *Front Microbiol* 2021;11:1–14.
 16. **Naveca FG, Nascimento V, de Souza VC, Corado A de L, Nascimento F, et al.** COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. *Nat Med* 2021;27:1230–1238.
 17. **Dejnirattisai W, Zhou D, Ginn HM, Duyvesteyn HME, Supasa P, et al.** The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*;184. Epub ahead of print 2021. DOI: 10.1016/j.cell.2021.02.032.

18. **Wang P, Casner RG, Nair MS, Wang M, Yu J, et al.** Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell Host Microbe* 2021;29:747-751.e4.
19. **Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, et al.** SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*. Epub ahead of print 2021. DOI: 10.1038/s41586-021-03944-y.
20. **Ren L, Zhang L, Chang D, Wang JJ, Hu Y, et al.** The kinetics of humoral response and its relationship with the disease severity in COVID-19. *Commun Biol*;3. Epub ahead of print 2020. DOI: 10.1038/s42003-020-01526-8.
21. **Julander JG, Trent DW, Monath TP.** Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. *Vaccine* 2011;29:6008–6016.
22. **Mason RA, Tauraso NM, Spertzel RO, Ginn RK.** Yellow Fever Vaccine: Direct Challenge of Monkeys Given Graded Doses of 17D Vaccine. *Appl Microbiol* 1973;25:539–544.
23. **Brazilian Ministry of Health.** Vacinação COVID-19 - doses aplicadas. <https://www.gov.br/saude/pt-br/vacinacao/> (2021).
24. **Sah P, Moghadas SM, Vilches TN, Shoukat A, Singer BH, et al.** Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas. *Lancet Infect Dis* 2021;21:1493–1494.
25. **Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, et al.** Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera. *J Gen Virol* 1989;70:37–43.
26. **Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, et al.** Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests. *Clin Vaccine Immunol* 2009;16:1052–1059.